Identification And Characterization Of A Novel Tumor Suppressor
Funder
National Health and Medical Research Council
Funding Amount
$591,997.00
Summary
Australia has the highest rate of skin cancer in the world, with over 380,000 people diagnosed every year. Of these, over 370,000 have non-melanoma skin cancers including squamous cell carcinoma and basal cell carcinoma. Our laboratory has identified a gene in mice that protects animals from squamous cell cancer. The studies proposed in this grant examine the mechanisms underpinning this protective role and may have important implications for the prevention of skin cancers in humans.
Defects In Epidermal Morphogenesis In Grainyhead-like Gene Deficient Mice
Funder
National Health and Medical Research Council
Funding Amount
$579,138.00
Summary
The cells of the skin play an essential role in the development of the mammalian embryo. They are critical for forming a protective barrier against infection and external toxins, for preventing excess fluid loss, for repair of defects and wounds , and for the generation of hair. Our laboratory has identified a family of genes that are critical for these processes. The aim of this study is to determine the relationship between these genes to further our understanding of the skin and its functions
Relationship Between Head Injury And Cognitive, Neurological And Biological Variables Associated With Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$252,849.00
Summary
This project will investigate in people over the age of 60 whether the features which predispose to Alzheimer’s disease are more prevalent in individuals who have sustained a head injury previously in their lives. If our findings suggest that a history of head injury increases the risk of Alzheimer's disease, we will be able to evaluate relationships with other medical and social variables and with lifestyle and dietary factors which may reduce this risk.
Characterisation Of Substance P Antagonists As A Novel Therapeutic Intervention For Use In Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$241,650.00
Summary
Traumatic brain injury (TBI) is responsible for more deaths in Australians under 45 years of age than any other cause. The economic and social cost of head injury to the community is enormous with billions of dollars spent each year on the management and rehabilitation of trauma patients. Despite the enormity of this public health problem, no effective treatment currently exists. A number of studies have demonstrated that much of the morbidity following TBI is associated with the development of ....Traumatic brain injury (TBI) is responsible for more deaths in Australians under 45 years of age than any other cause. The economic and social cost of head injury to the community is enormous with billions of dollars spent each year on the management and rehabilitation of trauma patients. Despite the enormity of this public health problem, no effective treatment currently exists. A number of studies have demonstrated that much of the morbidity following TBI is associated with the development of a secondary injury process that occurs between hours to days after the insult. This delayed progression of injury suggests that appropriate pharmacologic intervention can prevent, or at least attenuate, this secondary injury process with a resultant improvement in outcome. Over the past 15 years, a number of groups, including ours, have been investigating the secondary mechanisms associated with the development of functional deficits after TBI. Our previous studies have demonstrated that decline in brain free magnesium is associated with functional deficits after experimental brain injury, and that magnesium administration after injury can improve outcome. Magnesium is now on clinical trial as a pharmacologic intervention. Recent studies have suggested that magnesium decline facilitates neurogenic inflammation, which has been associated with oedema formation, oxidative damage and cell death. Although a number of neuropeptides have been implicated in this process, it is thought that substance P release is closely associated with these pathophysiological processes. Therefore, inhibiting neuropeptide release, or inhibiting substance P binding, may offer a novel therapeutic approach for the attenuation of oedema and development of neurologic deficits after TBI. This proposal will use a combined biochemical, pharmacologic and behavioural approach to characterise the role of neuropeptides in brain trauma, and attempt to develop a novel therapy for use in clinical trauma.Read moreRead less